Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The awards will be handed out at a gala event scheduled for October 9 at New York City’s Cipriani Wall Street.

Pleurisy Market Pleurisy Market is valued at USD 1.83 billion In 2024 and is expected to grow at the rate of CAGR of 6.94%, is expected to reach USD 3.23 billion by 2032 Innovating pleurisy care ...

Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.

Rakovina Therapeutics Inc. ('Rakovina” or the 'Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next ...

HYOGO, Japan I July 8, 2025 I JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) today announced that it has entered into a license agreement with Alexion, ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

The Milner Therapeutics Institute hosted its annual Symposium this week – a hybrid event welcoming 500 in-person delegates ...